Drugs / IDP-121
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05908409 | Jun 2023 → Dec 2025 overdue | B-cell chronic lymphocytic leukemia, high grade B-cell lymphoma, high-grade B-cell lymphoma double-hit/triple-hit, plasma cell myeloma | IDP Discovery Pharma S.L. | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02491060 | Sep 2015 → Jul 2016 | acne | Valeant Pharmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT02535871 | Sep 2015 → Jul 2016 | acne | Valeant Pharmaceuticals | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-26 | IDP Discovery Pharma S.L. | First patient dosed in a Phase 1/2 Clinical Trial of IDP-121, a direct cMyc protein inhibitor and degrader idp-pharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDP-121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05908409 ↗ |
| Route | Topical | “IDP-121 Lotion, applied topically to the face” NCT02491060 ↗ |
| Target | MYC | “specifically designed to directly target cMyc protein” NCT05908409 ↗ |